NCT04384250

Brief Summary

We will study genetic factors causing severe disease due to infection with SARS-COV-2 which may help to find targeted therapy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 10, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 12, 2020

Completed
20 days until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

March 11, 2025

Status Verified

March 1, 2025

Enrollment Period

3.6 years

First QC Date

May 10, 2020

Last Update Submit

March 8, 2025

Conditions

Genetic Basis of COVID-19 Infection

Keywords

SARS-COV-2, Genetics

Outcome Measures

Primary Outcomes (1)

  • Mutations leading to increase susceptibility to SARS-COV-2 infection

    Genetic susceptibility to COVID-19

    12 months

Interventions

Whole Exome SequencingDIAGNOSTIC_TEST

Genetic study of patients

Eligibility Criteria

Age1 Day - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

COVID-19 positive patients

You may qualify if:

  • severe COVID-19 infection

You may not qualify if:

  • Comorbidity ((DM, hypertension, Chronic liver or Kidney diseases, HIV, morbid obesity, Malignancy, Immunosuppressive therapy)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura University

Al Mansurah, Dakahlyia, 35516, Egypt

Location

MeSH Terms

Interventions

Exome

Intervention Hierarchy (Ancestors)

GenomeGenetic StructuresGenetic Phenomena

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Pediatric Immunology

Study Record Dates

First Submitted

May 10, 2020

First Posted

May 12, 2020

Study Start

June 1, 2020

Primary Completion

December 30, 2023

Study Completion

December 30, 2024

Last Updated

March 11, 2025

Record last verified: 2025-03

Locations

EG(1)